Revvity, today announced the launch of the IDS i20™ random access analyzer from EUROIMMUN, a fully automated platform for chemiluminescence immunoassays (ChLIA). CE marked and FDA listed, the IDS i20 offers greater reagent capacity and higher throughput than existing systems, enabling labs to consolidate multiple specialty tests onto a single instrument.
The IDS i20 can run up to 20 analytes from six diagnostic areas—including endocrinology, allergy, autoimmunity, infectious diseases, Alzheimer’s disease, and therapeutic drug monitoring—on one device. It provides a flexible alternative to manual or semi-automated analyzers traditionally used for these assays.
“With the IDS i20, we’re supporting customers in moving to fully automated workflows for enhanced immunodiagnostics,” said Dr. Bianca Huth, Chief Technical Officer at EUROIMMUN. “This system reflects decades of expertise in lab automation, built to meet laboratories’ needs for reliability, versatility, and ease of use.”
Capable of processing up to 140 tests per hour (assay dependent), the IDS i20 features a modern software interface designed for adaptability, scalability, and cybersecurity. Continuous sample and reagent loading, along with integrated cooling for ready-to-use cartridges, allows for non-stop operation—maximizing efficiency while minimizing hands-on time.